News

TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Dr. Tawanda Gumbo

Listen to Tawanda Gumbo Podcast

Summary: Dr. Tawanda Gumbo, an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.” The paper puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB but instead that the differences or fluctuations in the way patients absorb, metabolize and retain the drug in their bodies contributes to the emergence of resistance to TB drugs. In this interview, we discuss the recently published paper, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.

Dr. Gumbo’s research is focused on advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics, clinical trial simulations using Monte Carlo Methods, individualized Bayesian dose optimization, as well as, the molecular and cellular pharmacology of antituberculosis and other antimycobacterial agents.

Additional TB R&D News:

Recent exchange on the topic of Moxifloxacin use:

Rational use of moxifloxacin for tuberculosis treatment

Moxifloxacin for tuberculosis (Mendel & Springsklee)

Moxifloxacin for tuberculosis (Singh, et al.)

Moxifloxacin for tuberculosis — Authors’ reply

Other news links:

SymptomsofTuberculosis.Net Launches to Address Rising Concerns Over Tuberculosis and Symptoms of Tuberculosis

Biomedical company sets up in Memphis

Combating TB, the right way

Polio eradication has a lesson for TB control

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...